Entity

Time filter

Source Type


Le Guen E.,University Paris Est Creteil | Le Guen E.,French Institute of Health and Medical Research | Doukhan R.,University Paris Est Creteil | Doukhan R.,French Institute of Health and Medical Research | And 10 more authors.
Medecine/Sciences | Year: 2015

The recent discovery of anti-NMDA receptor antibodies and proof of their pathogenic effects in limbic encephalitides raised many questions among neuroscientist and physicians working in the field of schizophrenia. Indeed, this two conditions share several major clinical, pathophysiological or etiological aspects and some authors tend to consider some forms of schizophrenia as mild-encephalitis cases. Some studies have reported the presence of these antibodies in schizophrenic patient's sera without neurological symptoms. These findings suggest new therapeutic perspectives in some schizophrenic patients, despite a low seroprevalence and pathogenic effects that remain to be demonstrated. © 2015 médecine/sciences-Inserm. Source


Chaaben A.B.,Institute Salah Azaiz | Chaaben A.B.,Laboratoire Jean Dausset dImmunologie et dHistocompatibilite | Abaza H.,Institute Salah Azaiz | Douik H.,Institute Salah Azaiz | And 5 more authors.
Annales de Biologie Clinique | Year: 2014

Nasopharyngeal carcinoma (NPC) is a complex multifactorial disorder involving both genetic and environmental factors. Genetic predisposition linked to the immune system has been associated with various tumors. This involves genetic diversity of the genes encoding the molecules of the immune response such as inflammation and anti-tumor surveillance. In this work, we examined the impact of the immunogenetic diversity on the risk of the NPC in different populations studied. These data show that the interindividual variability of the genetic regulation of immune processes increases the risk of NPC in individuals previously predisposed due to other risk factors (genetic / environmental). This synthesis, in addition to the predictive aspects, could provide innovative research for the development of new therapeutic approaches. Source

Discover hidden collaborations